- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03606200
Swiss Primary Ciliary Dyskinesia Registry (CH-PCD)
Study Overview
Status
Conditions
Detailed Description
The Swiss Primary Ciliary Dyskinesia registry (CH-PCD) was founded in 2013 as a collaborative project between epidemiologists and adult and paediatric pulmonologists. It started as a pilot project in the canton of Bern and in 2014 was extended to include all Switzerland. The data centre of the SPCDR is located at the Institute of Social and Preventive Medicine at the University of Bern. It contributes data to the international PCD registry and other international studies such as the international PCD (iPCD) cohort.
Objectives of the CH-PCD:
The Swiss Primary Ciliary Dyskinesia Registry collects information on diagnosis, symptoms, treatment and follow-up of patients with PCD in Switzerland and provides data for national and international monitoring and research. In particular, it aims to:
- Identify all patients diagnosed with PCD in Switzerland.
- Collect population based data (incidence, prevalence, time trends and regional trends).
- Document diagnostic evaluations, treatments and participation in clinical trials.
- Document the clinical course of PCD, quality of life, morbidity and mortality.
- Establish a research platform for clinical, epidemiological and basic research.
Study design:
The CH-PCD is a patient registry. At baseline (inclusion of a patient to the registry), it collects retrospectively all available data since birth and it follows included patients throughout life until death or loss to follow up, collecting prospectively data at regular time intervals.
What data is collected:
The CH-PCD collects information on demographic characteristics (e.g. age, sex), diagnostic tests and clinical data about manifestations and management of the disease. It collects repeated follow-up data on growth, lung function, clinical manifestations from all affected organ systems, microbiology and imaging, lab results, therapeutic interventions (including surgery and physiotherapy) and hospitalisations. It also collects information on neonatal symptoms related to the disease and on the symptoms, that led to referral and PCD diagnosis.
Since 2020, the CH-PCD collects through questionnaire surveys patient-reported information on symptoms and lifestyle behaviours.
Study database:
The study database is web-based, using the Research Electronic Data Capture (REDCap) platform developed at Vanderbilt University. REDCap is widely used in academic research and allows data entry and extraction in various formats.
How to participate:
Patients with PCD who would like to participate to the registry as well as physicians who treat patients with PCD should contact the CH-PCD to receive the study information and informed consent forms.
For further details, please contact: spcdr@hin.ch
Funding:
The setting up of the CH-PCD (salaries, consumables and equipment) was funded by several Swiss funding bodies, including the Lung Leagues of Bern, St. Gallen, Vaud, Ticino and Valais and the Kantonalbernischer Hilfsbund.Research activities based on data included in the CH-PCD are funded by the Swiss National Science foundation (SNF 320030_173044, 320030B_192804 and PZ00P3_185923). The CH-PCD participated to the EU funded BEAT-PCD COST Action (BM1407) and participates to the BEAT-PCD clinical research collaboration supported by the European Respiratory Society.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Claudia E Kuehni, Prof
- Phone Number: 0041 316313507
- Email: spcdr@hin.ch
Study Contact Backup
- Name: Myrofora Goutaki, PD, MD-PhD
- Phone Number: 0041 316315973
- Email: spcdr@hin.ch
Study Locations
-
-
-
Bern, Switzerland, 3012
- Recruiting
- University of Bern
-
Contact:
- Claudia E Kuehni, Prof
- Phone Number: 0041 316313507
- Email: spcdr@hin.ch
-
Contact:
- Myrofora Goutaki, MD-PhD
- Phone Number: 0041 316315973
- Email: spcdr@hin.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients diagnosed with primary ciliary dyskinesia
- Signed informed consent or assent
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Height
Time Frame: every 3 months up to 80 years
|
Height z-scores calculated based on available national and international references
|
every 3 months up to 80 years
|
BMI
Time Frame: every 3 months up to 80 years
|
Body Mass Index (BMI) z-scores calculated based on available national and international references
|
every 3 months up to 80 years
|
Lung function measurements
Time Frame: every 3 months up to 80 years
|
Spirometric indices, particularly Forced expiratory volume in 1 sec (FEV1) and Forced vital capacity (FVC) z-scores calculated based on Global Lung Function Initiative (GLI) reference values
|
every 3 months up to 80 years
|
Measurement of nasal nitric oxide using breath analyzer
Time Frame: at study entry (in case patient is <5 years old at study entry, then the outcome will be assessed at age 5
|
Results of nasal nitric oxide measurement, performed for diagnosis
|
at study entry (in case patient is <5 years old at study entry, then the outcome will be assessed at age 5
|
Cilia ultrastructure identified using electron microscopy analysis
Time Frame: at study entry
|
Results of electron microscopy analysis of cilia, performed for diagnosis
|
at study entry
|
Ciliary beat frequency and beat pattern using video microscopy analysis
Time Frame: at study entry
|
Results of video microscopy analysis of cilia, performed for diagnosis
|
at study entry
|
Microbiological culture of respiratory samples
Time Frame: every 3 months up to 80 years
|
Results of microbiology cultures of respiratory samples (sputum, cough swabs, throat swabs, ear swabs, bronchoalveolar lavage) expressed in a qualitative (growth or no growth of pathogens) or semiquantitative way (the type of sample depends on the age of the patient and the clinic the sample was collected).
|
every 3 months up to 80 years
|
Antibiotic resistance of microbes isolated in microbiological cultures
Time Frame: every 3 months up to 80 years
|
Information on antibiotic resistance of microbes isolated in microbiological cultures (see outcome 7) of respiratory samples, expressed either semiquantitatively or by the value of minimum inhibitory concentration.
|
every 3 months up to 80 years
|
Chest computed tomography
Time Frame: every 3 months up to 80 years
|
Radiological findings from chest computed tomography
|
every 3 months up to 80 years
|
Sinus computed tomography
Time Frame: every 3 months up to 80 years
|
Radiological findings from sinus computed tomography
|
every 3 months up to 80 years
|
Vital status
Time Frame: every 3 months up to 80 years
|
Vital status of patient: has the patient died or is he/she still alive and in case of death what was the cause?
|
every 3 months up to 80 years
|
Clinical symptoms frequency
Time Frame: once a year up to 80 years
|
Frequency of respiratory symptoms recorded with a patient or parent-reported questionnaire
|
once a year up to 80 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Claudia E Kuehni, Prof, University of Bern
- Principal Investigator: Myrofora Goutaki, PD, MD-PhD, University of Bern
Publications and helpful links
General Publications
- Goutaki M, Eich MO, Halbeisen FS, Barben J, Casaulta C, Clarenbach C, Hafen G, Latzin P, Regamey N, Lazor R, Tschanz S, Zanolari M, Maurer E, Kuehni CE; Swiss PCD Registry (CH-PCD) Working Group. The Swiss Primary Ciliary Dyskinesia registry: objectives, methods and first results. Swiss Med Wkly. 2019 Jan 13;149:w20004. doi: 10.57187/smw.2019.20004. eCollection 2019 Jan 1.
- Goutaki M, Husler L, Lam YT, Koppe HM, Jung A, Lazor R, Muller L; Swiss PCD Research Group; Pedersen ESL, Kuehni CE. Respiratory symptoms of Swiss people with primary ciliary dyskinesia. ERJ Open Res. 2022 Apr 11;8(2):00673-2021. doi: 10.1183/23120541.00673-2021. eCollection 2022 Apr.
- Lam YT, Pedersen ESL, Schreck LD, Husler L, Koppe H, Belle FN, Clarenbach C, Latzin P; Swiss PCD research group; Kuehni CE, Goutaki M. Physical activity, respiratory physiotherapy practices, and nutrition among people with primary ciliary dyskinesia in Switzerland - a cross-sectional survey. Swiss Med Wkly. 2022 Aug 18;152:w30221. doi: 10.4414/smw.2022.w30221. eCollection 2022 Aug 15.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Neurologic Manifestations
- Congenital Abnormalities
- Bronchial Diseases
- Genetic Diseases, Inborn
- Otorhinolaryngologic Diseases
- Movement Disorders
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Abnormalities, Multiple
- Ciliopathies
- Bronchiectasis
- Respiratory System Abnormalities
- Dextrocardia
- Situs Inversus
- Dyskinesias
- Ciliary Motility Disorders
- Kartagener Syndrome
Other Study ID Numbers
- CH-PCD (SRDR)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Ciliary Dyskinesia
-
University Hospital MuensterAssistance Publique - Hôpitaux de Paris; University of Pisa; Medical University... and other collaboratorsRecruitingPrimary Ciliary Dyskinesia (PCD)Germany
-
University of Alabama at BirminghamMassachusetts General HospitalRecruitingCovid19 | Sinusitis | Cystic Fibrosis | COPD | PCD - Primary Ciliary DyskinesiaUnited States
-
Connecticut Children's Medical CenterUConn HealthRecruiting
-
University Hospital MuensterUniversity of Pisa; Medical University of Vienna; Hacettepe University; Charite... and other collaboratorsRecruitingPrimary Ciliary Dyskinesia | Ciliary Motility DisordersGermany
-
The University of Texas Health Science Center,...RecruitingPrimary Ciliary DyskinesiaUnited States
-
Vanderbilt University Medical CenterRecruiting
-
The Hospital for Sick ChildrenProvincial Health Services AuthorityCompletedPrimary Ciliary DyskinesiaCanada
-
University of AlbertaCompleted
-
Gazi UniversityCompletedPrimary Ciliary DyskinesiaTurkey
-
ReCode TherapeuticsSano Genetics; ReverbaRecruitingPrimary Ciliary DyskinesiaUnited States